Loxo Oncology, Inc. (LOXO) Reached 12-Month High on Apr, 16 at $133.85

April 16, 2018 - By Jeanette Garcia

Loxo Oncology, Inc. (NASDAQ:LOXO) Corporate Logo

Big Money Sentiment decreased to 0.97 in 2017 Q4. It has change of 0.76, from 2017Q3’s 1.73. The ratio dropped due to Loxo Oncology, Inc. positioning: 29 sold and 43 reduced. 23 funds acquired stakes and 47 increased stakes. Investors holded 29.06 million in 2017Q3 but now own 124.82 million shares or 329.48% more.
Employees Retirement Association Of Colorado reported 1,179 shs. Rock Springs Ltd Partnership, a Maryland-based fund reported 310,000 shs. Parallax Volatility Advisers L P owns 3,486 shs. Opaleye Incorporated reported 4.75% in Loxo Oncology, Inc. (NASDAQ:LOXO). Atlantic Trust Grp Inc Limited Liability Co has 175 shs for 0% of their capital. Cornerstone Advsrs, Washington-based fund reported 330 shs. Rhumbline Advisers holds 22,073 shs or 0% of its capital. Royal Fincl Bank Of Canada reported 226 shs stake. Proshare Advisors Lc accumulated 19,521 shs. Alliancebernstein L P has invested 0.04% in Loxo Oncology, Inc. (NASDAQ:LOXO). Jasper Ridge L P stated it has 0.02% in Loxo Oncology, Inc. (NASDAQ:LOXO). Morgan Stanley reported 72,592 shs. National Bank Of Montreal Can has 0% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Sectoral Asset Mgmt Inc reported 152,185 shs stake. California Public Employees Retirement System reported 0.01% of its capital in Loxo Oncology, Inc. (NASDAQ:LOXO).

Loxo Oncology, Inc. registered $70.72 million net activity with 0 buys and 16 sales since December 8, 2017. On Friday, December 8 $20.63M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Bonita David P. On Tuesday, January 16 Van Naarden Jacob had sold 3,082 shs worth $271,866. AISLING CAPITAL III LP sold $20.13M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) on Tuesday, December 19. On Friday, December 8 250,000 shs were sold by ORBIMED ADVISORS LLC, worth $20.63M. The insider Bilenker Joshua H. sold 15,000 shs worth $1.32M. On Monday, January 22 the insider Naider Avi Z. sold $1.50 million.

Today Loxo Oncology, Inc. (NASDAQ:LOXO) with $133.85 stock price, reached one-year high with $140.54 PT or 5.00 % above. It was reported on Apr, 16 according to Barchart.com The company has $4.02 billion MC. At our $140.54 PT, the company worth will be $201.00 million more.

On during the last trading session the stock increased $10.86 or 8.83%, reaching $133.85.Loxo Oncology, Inc. has 699,387 shares volume, 73.74% up from normal. LOXO is uptrending and has moved 146.80% since April 16, 2017. The stock outperformed the S&P500 by 135.25%.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on May, 8. They expect $-0.44 earnings per share, up 54.17 % or $0.52 from last year’s $-0.96 per share. After $-0.69 actual earnings per share reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts -36.23 % EPS growth.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

In total 8 analysts cover Loxo Oncology (NASDAQ:LOXO). “Buy” rating has 8, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $151 highest and $95.0 lowest [Target] Loxo Oncology has $119.67 average [Target] or -10.59% below the current ($133.85) price. 13 are the (NASDAQ:LOXO)’s analyst reports since October 20, 2017 according to StockzIntelligence Inc. On Tuesday, November 14 the firm has “Strong Buy” rating given by IFS Securities. In Thursday, March 1 report Stifel Nicolaus maintained the stock with “Buy” rating. On Friday, October 20 the stock has “Buy” rating by Citigroup. On Thursday, November 2 the firm has “Buy” rating by Stifel Nicolaus given. On Wednesday, March 21 Morgan Stanley downgraded the shares of LOXO in report to “Equal-Weight” rating. The stock rating was initiated by Oppenheimer with “Buy” on Thursday, February 22. In Tuesday, November 14 report JMP Securities upgraded it to “Buy” rating and $95.0 target. On Monday, March 5 the stock has “Buy” rating by Citigroup. On Thursday, November 16 Citigroup maintained the shares of LOXO in report with “Buy” rating. On Wednesday, December 20 the firm has “Buy” rating by BTIG Research given.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States.The firm is valued at $4.02 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.Currently it has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: